
A new study has revealed that the anti-herpes drug acyclovir can slow down HIV infection, but with the risk that treated cells may promote the emergence of multi-drug resistant HIV variants.
Moira McMahon and colleagues at Johns Hopkins used a sensitive infection assay of white blood cells, and observed that acyclovir could directly inhibit HIV replication.
Advertisement
The researchers said that the drug particularly targeted the reverse transcriptase (RT) enzyme, which converts HIV's RNA into DNA to enable it to replicate.
However, as early as five days after initial infection, a mutant version of HIV (V75I) appeared in the cells, and spread to comprise over 90 per cent of the viral population within 94 days.
The V75I strain is part of the resistance pathway to many drugs, including the commonly used RT inhibitors.
Based on their observations, the researchers came to the conclusion that acyclovir could be a great model for designing future HIV treatments, but also could be a risky drug if given to HSV patients co-infected with HIV by potentially promoting cross-resistance to current treatments.
An article on the study has been published in JBC online.
Source: ANI
SRM
Advertisement
The V75I strain is part of the resistance pathway to many drugs, including the commonly used RT inhibitors.
Based on their observations, the researchers came to the conclusion that acyclovir could be a great model for designing future HIV treatments, but also could be a risky drug if given to HSV patients co-infected with HIV by potentially promoting cross-resistance to current treatments.
An article on the study has been published in JBC online.
Source: ANI
SRM
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News

Promising test results on a substance offer hope for developing medications or vaccines against the increasing Zika virus cases in 2023.

The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.

Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.

Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.

The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.